BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gibiansky L, Giraudon M, Rayner CR, Brennan BJ, Subramoney V, Robson R, Kamal MA. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment. J Pharmacokinet Pharmacodyn 2015;42:225-36. [PMID: 25821064 DOI: 10.1007/s10928-015-9411-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Huang MF, Lin YR, Chang YT, Shiue YL, Liang SS. Reductive amination assistance for quantification of oseltamivir phosphate and oseltamivir carboxylate by HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1087-1088:23-8. [PMID: 29702353 DOI: 10.1016/j.jchromb.2018.03.040] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. Br J Clin Pharmacol 2021. [PMID: 34449090 DOI: 10.1111/bcp.15059] [Reference Citation Analysis]
3 Tripp R, Hanson J. Inhaled Countermeasures for Respiratory Tract Viruses. In: Kwok P, Chan H, editors. Advances in Pulmonary Drug Delivery. Taylor & Francis Group: CRC Press; 2016. pp. 93-130. [DOI: 10.1201/9781315311975-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. Br J Clin Pharmacol 2021;87:1359-68. [PMID: 32808306 DOI: 10.1111/bcp.14523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. J Clin Pharmacol 2021;61:614-27. [PMID: 33145788 DOI: 10.1002/jcph.1771] [Reference Citation Analysis]
6 Karsch K, Chen X, Miera O, Peters B, Obermeier P, Francis RC, Amann V, Duwe S, Fraaij P, Heider A, de Zwart M, Berger F, Osterhaus A, Schweiger B, Rath B. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Eur J Drug Metab Pharmacokinet 2017;42:155-64. [PMID: 26994602 DOI: 10.1007/s13318-016-0330-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gibiansky L, Ravva P, Parrott NJ, Bhardwaj R, Zwanziger E, Grimsey P, Clinch B, Sturm S. Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants. Clin Pharmacol Ther 2020;108:126-35. [PMID: 31957010 DOI: 10.1002/cpt.1791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mitha E, Krivan G, Jacobs F, Nagler A, Alrabaa S, Mykietiuk A, Kenwright A, Le Pogam S, Clinch B, Vareikiene L. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther 2019;8:613-26. [PMID: 31667696 DOI: 10.1007/s40121-019-00271-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
9 Chairat K, Jittamala P, Hanpithakpong W, Day NP, White NJ, Pukrittayakamee S, Tarning J. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol 2016;81:1103-12. [PMID: 26810861 DOI: 10.1111/bcp.12892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]